Progyny, Inc. (NASDAQ:PGNY) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 6.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,186,027 shares of the company’s stock after purchasing an additional 74,740 shares during the period. Dimensional Fund Advisors LP owned 1.39% of Progyny worth $20,458,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Leibman Financial Services Inc. boosted its stake in Progyny by 100.7% during the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock worth $1,096,000 after buying an additional 31,872 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after acquiring an additional 695,740 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of Progyny during the 4th quarter valued at about $989,000. Barclays PLC grew its holdings in shares of Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock valued at $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. increased its position in Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock worth $22,989,000 after purchasing an additional 456,853 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several analyst reports. BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group increased their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Stock Up 0.2 %

Progyny stock opened at $23.41 on Thursday. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $32.99. The firm has a market cap of $2.01 billion, a PE ratio of 40.36, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. The company’s 50 day moving average is $21.93 and its two-hundred day moving average is $19.43.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.